CL2011002637A1 - Compuestos derivados del acido bifenil-2-il-carbamico, agonista de receptores muscarinos y antagonista b2 adrenergicos; proceso de preparacion de estos; compuesto intermediario; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades respiratorias. - Google Patents

Compuestos derivados del acido bifenil-2-il-carbamico, agonista de receptores muscarinos y antagonista b2 adrenergicos; proceso de preparacion de estos; compuesto intermediario; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades respiratorias.

Info

Publication number
CL2011002637A1
CL2011002637A1 CL2011002637A CL2011002637A CL2011002637A1 CL 2011002637 A1 CL2011002637 A1 CL 2011002637A1 CL 2011002637 A CL2011002637 A CL 2011002637A CL 2011002637 A CL2011002637 A CL 2011002637A CL 2011002637 A1 CL2011002637 A1 CL 2011002637A1
Authority
CL
Chile
Prior art keywords
biphenyl
treatment
pharmaceutical composition
carbamic acid
agonist
Prior art date
Application number
CL2011002637A
Other languages
English (en)
Inventor
Adam Hughes
Daniel Chen Yan Fleury Melissa Jacobsen John R Stangeland Eric L Wilson Richard D Yen Rose Byun
Original Assignee
Theravance Respiratory Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Respiratory Co Llc filed Critical Theravance Respiratory Co Llc
Publication of CL2011002637A1 publication Critical patent/CL2011002637A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados del ácido bifenil-2-il-carbamico; proceso de preparación; compuestos intermediarios; composición farmacéutica; y uso en el tratamiento de un trastorno pulmonar.
CL2011002637A 2009-04-23 2011-10-21 Compuestos derivados del acido bifenil-2-il-carbamico, agonista de receptores muscarinos y antagonista b2 adrenergicos; proceso de preparacion de estos; compuesto intermediario; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades respiratorias. CL2011002637A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
CL2011002637A1 true CL2011002637A1 (es) 2012-04-27

Family

ID=42272140

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002637A CL2011002637A1 (es) 2009-04-23 2011-10-21 Compuestos derivados del acido bifenil-2-il-carbamico, agonista de receptores muscarinos y antagonista b2 adrenergicos; proceso de preparacion de estos; compuesto intermediario; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades respiratorias.

Country Status (32)

Country Link
US (14) US8138345B2 (es)
EP (3) EP2421849B1 (es)
JP (3) JP5671006B2 (es)
KR (1) KR101769061B1 (es)
CN (2) CN103936716B (es)
AR (1) AR076412A1 (es)
AU (1) AU2010239522B2 (es)
BR (1) BRPI1014877B8 (es)
CA (1) CA2758505C (es)
CL (1) CL2011002637A1 (es)
CO (1) CO6440584A2 (es)
CY (2) CY1119008T1 (es)
DK (3) DK2599778T3 (es)
ES (3) ES2715965T3 (es)
HK (1) HK1165799A1 (es)
HR (3) HRP20130468T1 (es)
HU (2) HUE035049T2 (es)
IL (1) IL215554A (es)
LT (2) LT2599778T (es)
MX (1) MX2011011156A (es)
MY (1) MY158339A (es)
NZ (1) NZ595850A (es)
PL (3) PL2599778T3 (es)
PT (3) PT3210981T (es)
RU (2) RU2676686C2 (es)
SG (1) SG175330A1 (es)
SI (3) SI2421849T1 (es)
SM (1) SMT201300060B (es)
TR (1) TR201903556T4 (es)
TW (2) TWI513693B (es)
WO (1) WO2010123766A1 (es)
ZA (1) ZA201107743B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2715965T3 (es) 2009-04-23 2019-06-07 Theravance Respiratory Co Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta 2 adrenérgico
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
CA2838777C (en) 2011-06-10 2019-04-30 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN103562198B (zh) 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
RU2661877C2 (ru) 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
CA2893626C (en) 2012-12-06 2021-08-24 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
WO2016180349A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
TW201730150A (zh) * 2016-01-22 2017-09-01 Sichuan Haisco Pharmaceutical Co Ltd 氮雜環醯胺衍生物、其製備方法及醫藥用途
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US11447485B2 (en) 2016-12-14 2022-09-20 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quanternary ammonium salt structure
WO2018211530A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
MXPA02005596A (es) * 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
DK1305329T4 (da) 2000-08-05 2015-06-15 Glaxo Group Ltd 6alpha, 9alpha-difluor-17alpha-(2-furanylcarboxyl)oxy-11beta-hydroxy-16alpha-methyl-3-oxo-androst-1,4-dien-17-carbothiosyre-S-fluormethylester som et antiinflammatorisk middel
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US7151671B2 (en) * 2001-12-04 2006-12-19 Tokyo R & D Co., Ltd. Power supply
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239970B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
RS50538B (sr) 2004-01-22 2010-05-07 Pfizer Limited Sulfonamidni derivati namenjeni lečenju bolesti
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
RU2417617C2 (ru) 2006-02-08 2011-05-10 Фуджи Ойл Юроп Продукты питания с низким содержанием насыщенных и транс-изомерных ненасыщенных жиров
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
ES2715965T3 (es) 2009-04-23 2019-06-07 Theravance Respiratory Co Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta 2 adrenérgico

Also Published As

Publication number Publication date
US20130331364A1 (en) 2013-12-12
PT3210981T (pt) 2019-04-01
JP5965440B2 (ja) 2016-08-03
EP3210981B1 (en) 2019-01-02
HRP20170960T1 (hr) 2017-09-22
JP5671006B2 (ja) 2015-02-18
RU2011147374A (ru) 2013-05-27
US10358433B2 (en) 2019-07-23
PT2599778T (pt) 2017-06-06
US8138345B2 (en) 2012-03-20
US9975875B2 (en) 2018-05-22
IL215554A (en) 2014-08-31
US20200165223A1 (en) 2020-05-28
HUE042975T2 (hu) 2019-07-29
US8551978B2 (en) 2013-10-08
ZA201107743B (en) 2012-06-27
SG175330A1 (en) 2011-11-28
US20150274697A1 (en) 2015-10-01
SI2599778T1 (sl) 2017-08-31
BRPI1014877A8 (pt) 2018-03-13
ES2635358T3 (es) 2017-10-03
TWI513693B (zh) 2015-12-21
LT3210981T (lt) 2019-04-10
US9394275B2 (en) 2016-07-19
CN103936716B (zh) 2016-09-07
JP2015147807A (ja) 2015-08-20
SI2421849T1 (sl) 2013-07-31
EP2599778B1 (en) 2017-04-12
US20190300504A1 (en) 2019-10-03
ES2715965T3 (es) 2019-06-07
PL2599778T3 (pl) 2018-01-31
PT2421849E (pt) 2013-05-27
US10590107B2 (en) 2020-03-17
TW201546057A (zh) 2015-12-16
US20210024493A1 (en) 2021-01-28
AU2010239522B2 (en) 2015-07-02
US10836744B2 (en) 2020-11-17
HRP20130468T1 (en) 2013-06-30
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
MY158339A (en) 2016-09-30
EP2421849B1 (en) 2013-04-03
ES2417339T3 (es) 2013-08-07
US10138220B1 (en) 2018-11-27
AU2010239522A1 (en) 2011-11-10
US20190047984A1 (en) 2019-02-14
CN102405218A (zh) 2012-04-04
DK2421849T3 (da) 2013-07-01
BRPI1014877B1 (pt) 2020-11-10
NZ595850A (en) 2013-05-31
TR201903556T4 (tr) 2019-04-22
BRPI1014877A2 (pt) 2016-04-12
SMT201300060B (it) 2013-07-09
US9682957B2 (en) 2017-06-20
US20170096412A1 (en) 2017-04-06
HK1165799A1 (en) 2012-10-12
RU2676686C2 (ru) 2019-01-10
CN102405218B (zh) 2014-06-04
US20130137665A1 (en) 2013-05-30
EP2421849A1 (en) 2012-02-29
PL2421849T3 (pl) 2013-08-30
TWI570115B (zh) 2017-02-11
WO2010123766A1 (en) 2010-10-28
IL215554A0 (en) 2011-12-29
JP2014210816A (ja) 2014-11-13
CO6440584A2 (es) 2012-05-15
CY1119008T1 (el) 2018-01-10
US9771350B2 (en) 2017-09-26
MX2011011156A (es) 2011-11-04
US20100273755A1 (en) 2010-10-28
KR20110138292A (ko) 2011-12-26
EP2599778A1 (en) 2013-06-05
PL3210981T3 (pl) 2019-06-28
US20170362200A1 (en) 2017-12-21
HRP20190417T1 (hr) 2019-04-19
DK2599778T3 (en) 2017-06-26
KR101769061B1 (ko) 2017-08-17
RU2015101032A (ru) 2015-06-27
SI3210981T1 (sl) 2019-05-31
US20160361304A1 (en) 2016-12-15
BRPI1014877B8 (pt) 2021-05-25
CA2758505C (en) 2017-03-07
EP3210981A1 (en) 2017-08-30
US9000173B2 (en) 2015-04-07
US20170226082A1 (en) 2017-08-10
CY1121601T1 (el) 2020-05-29
RU2015101032A3 (es) 2018-07-30
JP2012524783A (ja) 2012-10-18
AR076412A1 (es) 2011-06-08
CN103936716A (zh) 2014-07-23
CA2758505A1 (en) 2010-10-28
DK3210981T3 (en) 2019-04-01
HUE035049T2 (en) 2018-05-02
US20140323733A1 (en) 2014-10-30
TW201041866A (en) 2010-12-01
RU2543716C2 (ru) 2015-03-10
LT2599778T (lt) 2017-08-25

Similar Documents

Publication Publication Date Title
CL2011002637A1 (es) Compuestos derivados del acido bifenil-2-il-carbamico, agonista de receptores muscarinos y antagonista b2 adrenergicos; proceso de preparacion de estos; compuesto intermediario; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades respiratorias.
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201201541A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
EA201300869A1 (ru) Морфинановые соединения
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
ECSP10010439A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EA201300388A1 (ru) Соединения замещенного бензамида
CL2011002103A1 (es) Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4.
MX2011012993A (es) Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos.
EA201500651A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CR11856A (es) Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos b2 para el tratamiento de trastornos respiratorios
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique